Given the high cost of CAD-CHM, a thorough assessment of its cost-effectiveness as a first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma is imperative to ensure both economic feasibility and equitable access within resource-constrained healthcare systems. This evidence concerns the gene ERBB2 and adenocarcinoma.